This is a preview of subscription content, log in via an institution to check access.
Notes
Costs (2020 values) included those for drugs and genetic testing, and treatment costs of minor bleeding, major bleeding, nonfatal MI, nonfatal stroke, post-MI, post-stroke, and death.
Reference
Claassens DMF, et al. Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial American Journal of Cardiovascular Drugs : 9 Sep 2021. Available from: URL: https://doi.org/10.1007/s40256-021-00496-4
Rights and permissions
About this article
Cite this article
In patients undergoing primary PCI, CYP2C19 genotype-guided treatment is a cost-effective option. PharmacoEcon Outcomes News 887, 15 (2021). https://doi.org/10.1007/s40274-021-08031-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08031-1